Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Citation",
"id" : "179631",
"meta" : {
"versionId" : "21",
"lastUpdated" : "2025-10-13T12:34:35.118Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
"language" : "en",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Citation 179631</b></p><a name=\"179631\"> </a><a name=\"hc179631\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 21; Last updated: 2025-10-13 12:34:35+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-journal-article-citation.html\">JournalArticleCitation</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"https://fevir.net/resources/Citation/179631\">https://fevir.net/resources/Citation/179631</a></p><p><b>identifier</b>: FEvIR Object Identifier/179631, <code>https://pubmed.ncbi.nlm.nih.gov</code>/19029421</p><p><b>title</b>: 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p><p><b>status</b>: Active</p><p><b>author</b>: Computable Publishing®: MEDLINE-to-FEvIR Converter: </p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"http://terminology.hl7.org/7.1.0/CodeSystem-citation-classification-type.html#citation-classification-type-fevir-platform-use\">Citation Classification Type: fevir-platform-use</a> (FEvIR Platform Use)</td><td><span title=\"Codes:{http://terminology.hl7.org/CodeSystem/citation-artifact-classifier medline-base}\">Medline Base</span></td></tr></table><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div><p><b>approvalDate</b>: 2009-01-13</p><p><b>lastReviewDate</b>: 2023-02-02</p><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/citation-classification-type citation-source}\">Citation Source</span></p><p><b>classifier</b>: <span title=\"Codes:\">MEDLINE</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/citation-classification-type medline-owner}\">MEDLINE Citation Owner</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value NLM}\">National Library of Medicine, Index Section</span></p></blockquote><p><b>currentState</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type medline-medline}\">Medline Citation Status of Medline</span>, <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-publication-status-ppublish}\">PubMed PublicationStatus of ppublish</span></p><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pubmed}\">PubMed Pubstatus of Pubmed</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-medline}\">PubMed Pubstatus of Medline</span></p><p><b>period</b>: ?? --> 2009-01-14 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-entrez}\">PubMed Pubstatus of Entrez</span></p><p><b>period</b>: ?? --> 2008-11-26 09:00:00+0000</p></blockquote><blockquote><p><b>statusDate</b></p><p><b>activity</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-status-type pubmed-pubstatus-pmc-release}\">PubMed Pubstatus of PMC release</span></p><p><b>period</b>: ?? --> 2009-12-20</p></blockquote><blockquote><p><b>citedArtifact</b></p><p><b>identifier</b>: <code>https://pubmed.ncbi.nlm.nih.gov</code>/19029421, <code>https://www.ncbi.nlm.nih.gov/pmc/</code>/PMC3864402, <code>https://doi.org</code>/10.1200/JCO.2007.15.9830, pii/JCO.2007.15.9830</p><h3>Titles</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://terminology.hl7.org/CodeSystem/title-type primary}\">Primary title</span></td><td><div><p>Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</p>\n</div></td></tr></table><h3>Abstracts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type primary-human-use}\">Primary human use</span></td><td><div><p><strong>PURPOSE:</strong> We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.\n<strong>PATIENTS AND METHODS:</strong> Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.\n<strong>RESULTS:</strong> Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.\n<strong>CONCLUSION:</strong> There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype.</p>\n</div></td></tr></table><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/17237035/\">https://pubmed.ncbi.nlm.nih.gov/17237035/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/7679039/\">https://pubmed.ncbi.nlm.nih.gov/7679039/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/11027418/\">https://pubmed.ncbi.nlm.nih.gov/11027418/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/9815636/\">https://pubmed.ncbi.nlm.nih.gov/9815636/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/10561202/\">https://pubmed.ncbi.nlm.nih.gov/10561202/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/11134194/\">https://pubmed.ncbi.nlm.nih.gov/11134194/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/12610188/\">https://pubmed.ncbi.nlm.nih.gov/12610188/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/15470214/\">https://pubmed.ncbi.nlm.nih.gov/15470214/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/15470213/\">https://pubmed.ncbi.nlm.nih.gov/15470213/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/6337697/\">https://pubmed.ncbi.nlm.nih.gov/6337697/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/3523938/\">https://pubmed.ncbi.nlm.nih.gov/3523938/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/2213104/\">https://pubmed.ncbi.nlm.nih.gov/2213104/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/9267791/\">https://pubmed.ncbi.nlm.nih.gov/9267791/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/9123707/\">https://pubmed.ncbi.nlm.nih.gov/9123707/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/9619712/\">https://pubmed.ncbi.nlm.nih.gov/9619712/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/10472324/\">https://pubmed.ncbi.nlm.nih.gov/10472324/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/10524892/\">https://pubmed.ncbi.nlm.nih.gov/10524892/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/11256836/\">https://pubmed.ncbi.nlm.nih.gov/11256836/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/14706014/\">https://pubmed.ncbi.nlm.nih.gov/14706014/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>citation</b>: </p><div><p>Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993</p>\n</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>citation</b>: </p><div><p>Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979</p>\n</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>citation</b>: </p><div><p>Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982</p>\n</div></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/16921051/\">https://pubmed.ncbi.nlm.nih.gov/16921051/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/16170163/\">https://pubmed.ncbi.nlm.nih.gov/16170163/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/10694556/\">https://pubmed.ncbi.nlm.nih.gov/10694556/</a></p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cites</p><p><b>classifier</b>: <span title=\"Codes:{http://hl7.org/fhir/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>citation</b>: </p><div><p>Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008</p>\n</div><p><b>target</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/18207190/\">https://pubmed.ncbi.nlm.nih.gov/18207190/</a></p></blockquote><blockquote><p><b>publicationForm</b></p><blockquote><p><b>publishedIn</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/published-in-type D020492}\">Periodical</span></p><p><b>identifier</b>: Electronic ISSN Type/1527-7755, ISOAbbreviation/J Clin Oncol, ISSN Linking/0732-183X, Medline Title Abbreviation/J Clin Oncol, NLM Unique ID/8309333</p><p><b>title</b>: Journal of clinical oncology : official journal of the American Society of Clinical Oncology</p><p><b>publisherLocation</b>: United States</p></blockquote><p><b>citedMedium</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-medium internet}\">Internet</span></p><p><b>volume</b>: 26</p><p><b>issue</b>: 36</p><p><b>articleDate</b>: 2008-12-20</p><p><b>pageString</b>: 5936-42</p></blockquote><blockquote><p><b>publicationForm</b></p><p><b>citedMedium</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-medium internet-without-issue}\">Internet without issue</span></p><p><b>articleDate</b>: 2008-11-24</p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/artifact-url-classifier abstract}\">Abstract</span></p><p><b>url</b>: <a href=\"https://pubmed.ncbi.nlm.nih.gov/19029421/\">https://pubmed.ncbi.nlm.nih.gov/19029421/</a></p></blockquote><blockquote><p><b>webLocation</b></p><p><b>classifier</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/artifact-url-classifier doi-based}\">DOI Based</span></p><p><b>url</b>: <a href=\"https://doi.org/10.1200/JCO.2007.15.9830\">https://doi.org/10.1200/JCO.2007.15.9830</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type publishing-model}\">Publishing Model</span></p><p><b>classifier</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/citation-artifact-classifier Print-Electronic}\">Print Electronic</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type chemical}\">Chemical</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000726}\">Androgen Antagonists</span>, <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000903}\">Antibiotics, Antineoplastic</span>, <span title=\"Codes:{https://www.nlm.nih.gov/mesh D018906}\">Antineoplastic Agents, Alkylating</span>, <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000972}\">Antineoplastic Agents, Phytogenic</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 35LT29625A}, {https://www.nlm.nih.gov/mesh D004961}\">Estramustine</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 5V9KLZ54CY}, {https://www.nlm.nih.gov/mesh D014747}\">Vinblastine</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances 80168379AG}, {https://www.nlm.nih.gov/mesh D004317}\">Doxorubicin</span>, <span title=\"Codes:{https://www.cas.org/support/documentation/chemical-substances R9400W927I}, {https://www.nlm.nih.gov/mesh D007654}\">Ketoconazole</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">MeSH heading</span></p><p><b>artifactAssessment</b>: <a href=\"#hc179631/meshHeading0\">ArtifactAssessment: artifact[x] = this resource</a></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type publication-type}\">Publication type</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D017428}\">Clinical Trial, Phase III</span>, <span title=\"Codes:{https://www.nlm.nih.gov/mesh D016428}\">Journal Article</span>, <span title=\"Codes:{https://www.nlm.nih.gov/mesh D016449}\">Randomized Controlled Trial</span></p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type knowledge-artifact-type}\">Knowledge Artifact Type</span></p><p><b>classifier</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/citation-artifact-classifier D016428}\">Journal Article</span></p><p><b>artifactAssessment</b>: Classifier added by Computable Publishing LLC</p></blockquote><blockquote><p><b>classification</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type citation-subset}\">Citation subset</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset IM}\">IM</span></p></blockquote><blockquote><p><b>contributorship</b></p><p><b>complete</b>: true</p><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor0\">Millikan RE</a></p><p><b>forenameInitials</b>: RE</p><p><b>affiliation</b>: Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor1\">Wen S</a></p><p><b>forenameInitials</b>: S</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor2\">Pagliaro LC</a></p><p><b>forenameInitials</b>: LC</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor3\">Brown MA</a></p><p><b>forenameInitials</b>: MA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor4\">Moomey B</a></p><p><b>forenameInitials</b>: B</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor5\">Do KA</a></p><p><b>forenameInitials</b>: KA</p></blockquote><blockquote><p><b>entry</b></p><p><b>contributor</b>: <a href=\"#hc179631/contributor6\">Logothetis CJ</a></p><p><b>forenameInitials</b>: CJ</p></blockquote></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor0</b></p><a name=\"179631/contributor0\"> </a><a name=\"hc179631/contributor0\"> </a><p><b>name</b>: Randall E Millikan </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor1</b></p><a name=\"179631/contributor1\"> </a><a name=\"hc179631/contributor1\"> </a><p><b>name</b>: Sijin Wen </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor2</b></p><a name=\"179631/contributor2\"> </a><a name=\"hc179631/contributor2\"> </a><p><b>name</b>: Lance C Pagliaro </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor3</b></p><a name=\"179631/contributor3\"> </a><a name=\"hc179631/contributor3\"> </a><p><b>name</b>: Melissa A Brown </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor4</b></p><a name=\"179631/contributor4\"> </a><a name=\"hc179631/contributor4\"> </a><p><b>name</b>: Brenda Moomey </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor5</b></p><a name=\"179631/contributor5\"> </a><a name=\"hc179631/contributor5\"> </a><p><b>name</b>: Kim-Anh Do </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Practitioner #contributor6</b></p><a name=\"179631/contributor6\"> </a><a name=\"hc179631/contributor6\"> </a><p><b>name</b>: Christopher J Logothetis </p></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: ArtifactAssessment #meshHeading0</b></p><a name=\"179631/meshHeading0\"> </a><a name=\"hc179631/meshHeading0\"> </a><p><b>artifact</b>: <a href=\"#hc179631\">Citation 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.</a></p><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000328}\">Adult</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000368}\">Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000369}\">Aged, 80 and over</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000726}\">Androgen Antagonists</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000627}\">therapeutic use</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000903}\">Antibiotics, Antineoplastic</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D018906}\">Antineoplastic Agents, Alkylating</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000972}\">Antineoplastic Agents, Phytogenic</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D000971}\">Antineoplastic Combined Chemotherapy Protocols</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000627}\">therapeutic use</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49488}\">Yes</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D004317}\">Doxorubicin</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D004961}\">Estramustine</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D006801}\">Humans</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D007654}\">Ketoconazole</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D008297}\">Male</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D008875}\">Middle Aged</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D009362}\">Neoplasm Metastasis</span></p><p><b>freeToShare</b>: true</p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">qualifier</span></td><td><span title=\"Codes:\">is not a major topic</span></td></tr></table></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D011471}\">Prostatic Neoplasms</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000188}\">drug therapy</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49488}\">Yes</span></td></tr></table></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000401}\">mortality</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote><blockquote><p><b>content</b></p><p><b>type</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type mesh-heading}\">components (if present) include qualifier codings</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh D014747}\">Vinblastine</span></p><p><b>freeToShare</b>: true</p><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:\">is not a major topic</span></p></blockquote><blockquote><p><b>component</b></p><p><b>type</b>: <span title=\"Codes:\">qualifier</span></p><p><b>classifier</b>: <span title=\"Codes:{https://www.nlm.nih.gov/mesh Q000008}\">administration & dosage</span></p><h3>Components</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Classifier</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">is Major topic</span></td><td><span title=\"Codes:{http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl C49487}\">No</span></td></tr></table></blockquote></blockquote></blockquote></div>"
},
"contained" : [
{
"resourceType" : "Practitioner",
"id" : "contributor0",
"name" : [
{
"family" : "Millikan",
"given" : [
"Randall E"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor1",
"name" : [
{
"family" : "Wen",
"given" : [
"Sijin"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor2",
"name" : [
{
"family" : "Pagliaro",
"given" : [
"Lance C"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor3",
"name" : [
{
"family" : "Brown",
"given" : [
"Melissa A"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor4",
"name" : [
{
"family" : "Moomey",
"given" : [
"Brenda"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor5",
"name" : [
{
"family" : "Do",
"given" : [
"Kim-Anh"
]
}
]
},
{
"resourceType" : "Practitioner",
"id" : "contributor6",
"name" : [
{
"family" : "Logothetis",
"given" : [
"Christopher J"
]
}
]
},
{
"resourceType" : "ArtifactAssessment",
"id" : "meshHeading0",
"artifactReference" : {
"reference" : "#",
"type" : "Citation"
},
"content" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000328",
"display" : "Adult",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000368",
"display" : "Aged",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000369",
"display" : "Aged, 80 and over",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000726",
"display" : "Androgen Antagonists",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000627",
"display" : "therapeutic use"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000903",
"display" : "Antibiotics, Antineoplastic",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D018906",
"display" : "Antineoplastic Agents, Alkylating",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000972",
"display" : "Antineoplastic Agents, Phytogenic",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000971",
"display" : "Antineoplastic Combined Chemotherapy Protocols",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000627",
"display" : "therapeutic use"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D004317",
"display" : "Doxorubicin",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D004961",
"display" : "Estramustine",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D006801",
"display" : "Humans",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D007654",
"display" : "Ketoconazole",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D008297",
"display" : "Male",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D008875",
"display" : "Middle Aged",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D009362",
"display" : "Neoplasm Metastasis",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D011471",
"display" : "Prostatic Neoplasms",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000188",
"display" : "drug therapy"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49488",
"display" : "Yes"
}
]
}
]
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000401",
"display" : "mortality"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
],
"text" : "components (if present) include qualifier codings"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D014747",
"display" : "Vinblastine",
"userSelected" : false
}
]
}
],
"freeToShare" : true,
"component" : [
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"text" : "is not a major topic"
}
]
},
{
"type" : {
"text" : "qualifier"
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "Q000008",
"display" : "administration & dosage"
}
]
}
],
"component" : [
{
"type" : {
"text" : "is Major topic"
},
"classifier" : [
{
"coding" : [
{
"system" : "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code" : "C49487",
"display" : "No"
}
]
}
]
}
]
}
]
}
]
}
],
"extension" : [
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Citation/179631",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "179631",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "19029421"
}
],
"title" : "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.",
"status" : "active",
"author" : [
{
"name" : "Computable Publishing®: MEDLINE-to-FEvIR Converter"
}
],
"publisher" : "Computable Publishing LLC",
"contact" : [
{
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
],
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"useContext" : [
{
"code" : {
"system" : "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code" : "fevir-platform-use",
"display" : "FEvIR Platform Use"
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code" : "medline-base",
"display" : "Medline Base",
"userSelected" : false
}
]
}
}
],
"copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"approvalDate" : "2009-01-13",
"lastReviewDate" : "2023-02-02",
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code" : "citation-source",
"display" : "Citation Source"
}
]
},
"classifier" : [
{
"text" : "MEDLINE"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code" : "medline-owner",
"display" : "MEDLINE Citation Owner"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value",
"code" : "NLM",
"display" : "National Library of Medicine, Index Section",
"userSelected" : false
}
]
}
]
}
],
"currentState" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "medline-medline",
"display" : "Medline Citation Status of Medline"
}
]
},
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-publication-status-ppublish",
"display" : "PubMed PublicationStatus of ppublish"
}
]
}
],
"statusDate" : [
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-pubmed",
"display" : "PubMed Pubstatus of Pubmed"
}
]
},
"period" : {
"end" : "2008-11-26T09:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-medline",
"display" : "PubMed Pubstatus of Medline"
}
]
},
"period" : {
"end" : "2009-01-14T09:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-entrez",
"display" : "PubMed Pubstatus of Entrez"
}
]
},
"period" : {
"end" : "2008-11-26T09:00:00.000Z"
}
},
{
"activity" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-status-type",
"code" : "pubmed-pubstatus-pmc-release",
"display" : "PubMed Pubstatus of PMC release"
}
]
},
"period" : {
"end" : "2009-12-20"
}
}
],
"citedArtifact" : {
"identifier" : [
{
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "19029421"
},
{
"system" : "https://www.ncbi.nlm.nih.gov/pmc/",
"value" : "PMC3864402"
},
{
"system" : "https://doi.org",
"value" : "10.1200/JCO.2007.15.9830"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "pii"
},
"value" : "JCO.2007.15.9830"
}
],
"title" : [
{
"type" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/title-type",
"code" : "primary",
"display" : "Primary title"
}
]
}
],
"text" : "Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer."
}
],
"abstract" : [
{
"type" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type",
"code" : "primary-human-use",
"display" : "Primary human use"
}
]
}
],
"text" : "**PURPOSE:** We conducted a phase III trial in patients with previously untreated metastatic prostate cancer to test the hypothesis that three 8-week cycles of ketoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to standard androgen deprivation, would delay the appearance of castrate-resistant disease.\n**PATIENTS AND METHODS:** Eligible patients had metastatic prostate cancer threatening enough to justify sustained androgen ablation and were fit enough for chemotherapy. The primary end point was time to castrate-resistant progression as shown by increasing prostate-specific antigen, new radiographic lesions, worsening cancer-related symptoms, or receipt of any other systemic therapy.\n**RESULTS:** Three hundred six patients were registered; 286 are reported. Median time to progression was 24 months (95% CI, 18 to 39 months) in the standard therapy arm, and 35 months (95% CI, 26 to 44 months) in the chemohormonal group (P = .39). At median follow-up of 6.4 years, overall survival was 5.4 years (95% CI, 4.7 to 7.8 years) in the standard therapy arm versus 6.1 years (95% CI, 5.1 to 10.1 years; P = .41). Prostate-specific antigen kinetics at the time of androgen ablation and the nadir after hormone treatment were strongly correlated with survival. Chemotherapy significantly increased the burden of therapy, with 51% of patients experiencing an adverse event of grade 3 or worse, especially thromboembolic events.\n**CONCLUSION:** There is no role for ketoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castrate-resistant phenotype."
}
],
"relatesTo" : [
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2007. CA Cancer J Clin 57:43-66, 2007",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/17237035/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "17237035",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098-1109, 1993",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/7679039/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "7679039",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Beer T, Raghavan D: Chemotherapy for hormone-refractory prostate cancer: Beauty is in the eye of the beholder. Prostate 45:184-193, 2000",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/11027418/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11027418",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Ellerhorst JA, Tu SM, Amato RJ, et al: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 3:2371-2376, 1997",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/9815636/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9815636",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Smith DC, Esper P, Strawderman M, et al: Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664-1671, 1999",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/10561202/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10561202",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Kelly WK, Curley T, Slovin S, et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53, 2001",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/11134194/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11134194",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Millikan RE, Thall PF, Lee SJ, et al: Randomized multicenter phase II trial of two multicomponent regimens in androgen independent prostate cancer. J Clin Oncol 21:878-883, 2003",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/12610188/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "12610188",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/15470214/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15470214",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/15470213/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "15470213",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/6337697/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "6337697",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Murphy GP, Huben RP, Priore R: Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology 28:36-40, 1986",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/3523938/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "3523938",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Osborne CK, Blumenstein B, Crawford ED, et al: Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: Final results of a randomized Southwest Oncology Group study. J Clin Oncol 8:1675-1682, 1990",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/2213104/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "2213104",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Pummer K, Lehnert M, Stettner H, et al: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81-85, 1997. (suppl)",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/9267791/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9267791",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Janknegt RA, Boon TA, van de Beek C, et al: Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. Urology 49:411-420, 1997",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/9123707/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9123707",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Fontana D, Bertetto O, Fasolis G, et al: Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases. Tumori 84:39-44, 1998",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/9619712/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "9619712",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Boel K, Van Poppel H, Goethuys H, et al: Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial. Anticancer Res 19:2157-2161, 1999",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/10472324/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10472324",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "de Reijke TM, Keuppens FI, Whelan P, et al: Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: The final results of a European organization for research in cancer therapy genitourinary group trial. J Urol 162:1658-1664, 1999",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/10524892/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10524892",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Kuriyama M, Takanhashi Y, Sahashi M, et al: Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol 31:18-24, 2001",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/11256836/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "11256836",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Noguchi M, Noda Shinshi, Yoshida M, et al: Chemohormonal therapy as primary treatment for metastatic prostate cancer: A randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103-109, 2004",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/14706014/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "14706014",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"citation" : "Fisher LD, Belle GV: Biostatistics: A Methodology For the Health Sciences. New York, NY, John Wiley, 1993"
},
{
"type" : "cites",
"citation" : "Randles RH, Wolfe DA: Introduction to the Theory of Nonparametric Statistics. New York, NY, John Wiley, 1979"
},
{
"type" : "cites",
"citation" : "Lawless JF: Statistical Models and Methods for Lifetime Data. New York, NY, John Wiley, 1982"
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from the Southwest Oncology Group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/16921051/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "16921051",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Stewart AJ, Scher HI, Chen M-H, et al: Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23:6556-6560, 2005",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/16170163/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "16170163",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Pettaway CA, Pisters LL, Troncoso P, et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 18:1050-1057, 2000",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/10694556/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "10694556",
"assigner" : {
"display" : "NLM"
}
}
}
},
{
"type" : "cites",
"classifier" : [
{
"coding" : [
{
"system" : "http://hl7.org/fhir/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article"
}
]
}
],
"citation" : "Friedman J, Dunn RL, Wood D, et al: Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179:911-916, 2008",
"targetReference" : {
"reference" : "https://pubmed.ncbi.nlm.nih.gov/18207190/",
"type" : "Citation",
"identifier" : {
"system" : "https://pubmed.ncbi.nlm.nih.gov",
"value" : "18207190",
"assigner" : {
"display" : "NLM"
}
}
}
}
],
"publicationForm" : [
{
"publishedIn" : {
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/published-in-type",
"code" : "D020492",
"display" : "Periodical"
}
]
},
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn",
"code" : "Electronic",
"display" : "Electronic"
}
],
"text" : "Electronic ISSN Type"
},
"system" : "https://portal.issn.org",
"value" : "1527-7755"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISOAbbreviation"
},
"system" : "https://www.issn.org/services/online-services/access-to-the-ltwa/",
"value" : "J Clin Oncol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "ISSN Linking"
},
"system" : "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/",
"value" : "0732-183X"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "Medline Title Abbreviation"
},
"system" : "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html",
"value" : "J Clin Oncol"
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "XX",
"display" : "Organization identifier"
}
],
"text" : "NLM Unique ID"
},
"system" : "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local",
"value" : "8309333"
}
],
"title" : "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
"publisherLocation" : "United States"
},
"citedMedium" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-medium",
"code" : "internet",
"display" : "Internet"
}
]
},
"volume" : "26",
"issue" : "36",
"articleDate" : "2008-12-20",
"pageString" : "5936-42"
},
{
"citedMedium" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-medium",
"code" : "internet-without-issue",
"display" : "Internet without issue"
}
]
},
"articleDate" : "2008-11-24"
}
],
"webLocation" : [
{
"classifier" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/artifact-url-classifier",
"code" : "abstract",
"display" : "Abstract"
}
]
}
],
"url" : "https://pubmed.ncbi.nlm.nih.gov/19029421/"
},
{
"classifier" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/artifact-url-classifier",
"code" : "doi-based",
"display" : "DOI Based"
}
]
}
],
"url" : "https://doi.org/10.1200/JCO.2007.15.9830"
}
],
"classification" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "publishing-model",
"display" : "Publishing Model",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code" : "Print-Electronic",
"display" : "Print Electronic",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "chemical",
"display" : "Chemical",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000726",
"display" : "Androgen Antagonists",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000903",
"display" : "Antibiotics, Antineoplastic",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D018906",
"display" : "Antineoplastic Agents, Alkylating",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D000972",
"display" : "Antineoplastic Agents, Phytogenic",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "35LT29625A",
"userSelected" : false
},
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D004961",
"display" : "Estramustine",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "5V9KLZ54CY",
"userSelected" : false
},
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D014747",
"display" : "Vinblastine",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "80168379AG",
"userSelected" : false
},
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D004317",
"display" : "Doxorubicin",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.cas.org/support/documentation/chemical-substances",
"code" : "R9400W927I",
"userSelected" : false
},
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D007654",
"display" : "Ketoconazole",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "mesh-heading",
"display" : "MeSH heading"
}
]
},
"artifactAssessment" : [
{
"reference" : "#meshHeading0",
"type" : "ArtifactAssessment"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "publication-type",
"display" : "Publication type"
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D017428",
"display" : "Clinical Trial, Phase III",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
},
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/mesh",
"code" : "D016449",
"display" : "Randomized Controlled Trial",
"userSelected" : false
}
]
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "knowledge-artifact-type",
"display" : "Knowledge Artifact Type",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code" : "D016428",
"display" : "Journal Article",
"userSelected" : false
}
]
}
],
"artifactAssessment" : [
{
"display" : "Classifier added by Computable Publishing LLC"
}
]
},
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code" : "citation-subset",
"display" : "Citation subset",
"userSelected" : false
}
]
},
"classifier" : [
{
"coding" : [
{
"system" : "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset",
"code" : "IM",
"display" : "IM",
"userSelected" : false
}
]
}
]
}
],
"contributorship" : {
"complete" : true,
"entry" : [
{
"contributor" : {
"reference" : "#contributor0",
"type" : "Practitioner",
"display" : "Millikan RE"
},
"forenameInitials" : "RE",
"affiliation" : [
{
"display" : "Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Pressler, CPB7.3462, Houston, TX 77030, USA. rmillika@mdanderson.org"
}
]
},
{
"contributor" : {
"reference" : "#contributor1",
"type" : "Practitioner",
"display" : "Wen S"
},
"forenameInitials" : "S"
},
{
"contributor" : {
"reference" : "#contributor2",
"type" : "Practitioner",
"display" : "Pagliaro LC"
},
"forenameInitials" : "LC"
},
{
"contributor" : {
"reference" : "#contributor3",
"type" : "Practitioner",
"display" : "Brown MA"
},
"forenameInitials" : "MA"
},
{
"contributor" : {
"reference" : "#contributor4",
"type" : "Practitioner",
"display" : "Moomey B"
},
"forenameInitials" : "B"
},
{
"contributor" : {
"reference" : "#contributor5",
"type" : "Practitioner",
"display" : "Do KA"
},
"forenameInitials" : "KA"
},
{
"contributor" : {
"reference" : "#contributor6",
"type" : "Practitioner",
"display" : "Logothetis CJ"
},
"forenameInitials" : "CJ"
}
]
}
}
}
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3.
Generated
2026-03-27
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change